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cause (rates after 10 years 21% vs. 71%, p  ! 0.0001), disease-
specific (12 vs. 37%, p = 0.009) and competing mortality (9 
vs. 33%, p = 0.02) differed significantly.  Conclusions: Some 
of the excess mortality in patients with poor-risk lymph 
node-positive prostate cancer may be attributed to in-
creased competing mortality, possibly caused by an interac-
tion between comorbid diseases and hormonally treated 
persistent or progressive prostate cancer. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 In the Western world, prostate cancer is the most com-
mon solid organ malignancy in males  [1] . In contrast to 
many other cancers, lymph node involvement in prostate 
cancer is frequently associated with long-term survival 
although definite cure is improbable. The prognostic fac-
tors predicting survival in men with lymph node-positive 
prostate cancer are still poorly defined  [2] . In this study, 
we evaluated several tumor-related and host-related vari-
ables as potential predictors of survival in this popula-
tion.
 Key Words 
 Urological neoplasms   Prostate cancer   Lymph nodes   
Radical prostatectomy   Prognostic factors   Overall 
survival   Disease-specific survival   Competing mortality 
 Abstract 
 Background: Factors predicting survival in men with lymph 
node-positive prostate cancer are still poorly defined.  Pa-
tients and Methods: 193 prostate cancer patients with his-
topathologically proven lymph node involvement with a 
median follow-up of 7.3 years were studied. 94% of patients 
received immediate hormonal therapy. Kaplan-Meier curves 
were calculated to evaluate overall survival rates and com-
pared with the log-rank test. Cumulative disease-specific 
and competing mortality rates were calculated by compet-
ing risk analysis and compared with the Pepe-Mori test. Cox 
proportional hazard models were used to determine the in-
dependent significance of predictors of all-cause mortality. 
 Results: Age (70 years or older vs. younger), Gleason score 
(8–10 vs. 7 or lower) and the number of involved nodes (3 or 
more vs. 1–2) were identified as independent predictors of 
all-cause mortality. When patients with 0–1 of these risk fac-
tors were compared with those with 2–3 risk factors, all-
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 Patients and Methods 
 Patient Sample 
 Between December 1st, 1992 and December 31st, 2005, of 
2,205 patients consecutively treated by radical prostatectomy, 194 
had histopathologically proven lymph node involvement and 
constituted the study group. Those in whom surgery was aborted 
after lymph node dissection were excluded. Institutional review 
board approval was obtained. Lymph node dissection was done 
along the external iliac vessels, with the bifurcation of the com-
mon iliac artery as proximal border and in the obturator fossa. 
The number of tumor-positive lymph nodes was available in all 
cases. The number of removed lymph nodes was available in 
189/194 patients. The mean number of removed nodes was 14 
(range 4–42) in those patients. Adjuvant hormonal treatment was 
recommended to patients with positive lymph nodes. In 136/194 
(70%) hormonal treatment was started within 3 months of sur-
gery; 182/194 patients (93%) received early hormonal treatment 
within 1 year of surgery. 43/194 patients (22%) had had received 
neoadjuvant hormonal treatment prior to surgery. PSA values 
were considered only in patients without neoadjuvant hormonal 
treatment. The mean PSA in those without neoadjuvant hormon-
al treatment was 20.6 ng/ml. One patient for whom no Gleason 
score was available was excluded leaving 193 patients for survival 
analysis. The mean age was 64.3 years. The mean follow-up in the 
censored patients was 8.4 years.
 Stratifications 
 After performing an exploratory analysis with three-sided 
stratifications of all variables (data not shown), two-sided strati-
fication promising maximal contrast were used for further analy-
ses. Besides tumor-related variables, the patients were stratified 
by age and four comorbidity classifications (the American Society 
of Anesthesiologists (ASA): physical status classification  [3] , the 
New York Heart Association (NYHA) classification of cardiac in-
sufficiency  [4] , the classification of angina pectoris of the Cana-
dian Cardiovascular Society (CCS)  [5] and the Charlson score  [6] ) 
( tables 1–3 ).
 Study Endpoints 
 Deaths from prostate cancer (presence of uncontrolled pro-
gressive disease at the time of death), deaths from competing 
causes (absence of uncontrolled progressive disease at the time of 
death) and death from any cause were the study endpoints.
 Statistical Analysis 
 Mantel-Haenszel hazard ratios and Kaplan-Meier overall sur-
vival curves were calculated. Comparisons were made with the 
log-rank test. The impact of different causes of death was ana-
lyzed by competing risk analysis  [7] . The related comparisons 
were made with the Pepe-Mori test. All p values are raw values. 
Cox proportional hazard models were used to determine the in-
dependent significance of prognostic variables. The statistical 
analyses were performed with own macros for the Statistical 
Analysis Systems (SAS Institute, Cary, N.C., USA) statistical 
package.
 Results 
 The results of the univariate analysis with overall 
mortality as endpoint are shown in  table 1 . In addition 
to age, numerous tumor- and comorbidity-related fac-
tors were significantly associated with overall mortality. 
Gleason score and tumor stage were significantly asso-
ciated with disease-specific mortality whereas the num-
ber of involved nodes did not reach the significance lev-
el ( table 2 ). Age, ASA classification and Charlson score 
were significantly associated with competing mortality 
( table 3 ). Using 70 years as the threshold, in the multi-
variate analysis, only age, Gleason score and the number 
of involved nodes were identified as independent pre-
dictors of overall survival. Age lost, however, its inde-
pendent prognostic significance when an age threshold 
of 65 years was chosen ( table 4 ). With the independent 
risk factors identified in the multivariate analysis with 
70 years as age threshold, the patients were subdivided 
into risk groups with distinctly different overall and dis-
ease-specific survival rates ( fig.  1 ,  2 ). Comparing pa-
tients with 0–1 versus 2–3 risk factors, overall, disease-
specific and competing mortality differed significantly 
( table 5 ).
 Discussion 
 In this study, the survival rates in patients with posi-
tive lymph nodes at radical prostatectomy differed wide-
ly. A sizeable minority of almost one third of patients 
without additional adverse prognostic factors had an ex-
cellent long-term survival rate (90% overall and 97% dis-
ease-specific survival after 10 years;  fig. 1 ,  2 ). This was 
similar to that usually seen in patients with node-nega-
tive disease. In the most unfavorable subset comprising 
about 25% of node-positive patients, however, only less 
than 30% survived for 10 years or more after radical pros-
tatectomy. However, even in this subgroup with poor sur-
vival only 37% of patients actually died from prostate 
cancer within 10 years ( fig. 1 ,  2 ;  table 5 ).
 The 10-year overall (66 vs. 67%) and disease-specific 
(82 vs. 82%) survival rates in this study were narrowly 
exactly the same as in a large bi-centric series treated be-
tween 1988 and 2003 with the same mean number of re-
moved lymph nodes (n = 14)  [8] . Something higher sur-
vival rates (76 and 87%) were observed in the immediate 
hormonal treatment arm in the randomized trial by 
Messing et al.  [9] , whereas in the deferred treatment arm 
(hormonal treatment at symptomatic progression) the 
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Table 1.  Results of the univariate analysis concerning overall mortality using two-sided stratifications
Category Proportion
of events
Hazard
ratio
95% CI p 10-year overall
survival, %
95% CI
All patients 51/193 66 57–74
Age <70 years 33/155 1 74 65–82
Age 70+ years 18/38 4.95 2.28–10.74 0.0001 22 5–48
Gleason score <8 12/88 1 83 70–90
Gleason score 8–10 39/105 3.30 1.89–5.77 0.0000 50 37–63
pT 2 5/44 1 84 63–94
pT 3–4 46/149 2.36 1.26–4.40 0.0070 61 50–70
1–2 positive nodes 31/148 1 73 63–81
>2 positive nodes 20/45 3.19 1.61–6.31 0.0009 44 25–61
PSA <10 ng/ml* 11/47 1 54 25–76
PSA 10+ ng/ml* 25/104 0.72 0.33–1.55 0.40 71 59–80
ASA class 1–2 40/166 1 71 61–79
ASA class 3 11/27 2.53 1.08–5.92 0.0328 39 16–62
NYHA class 0–1 47/187 1 68 59–76
NYHA class 2+ (9 years) 4/6 8.58 1.50–49.24 0.0159 21 1–60
CCS class 0–1 45/184 1 69 59–76
CCS class 2+ 6/9 5.71 1.50–21.72 0.0107 33 8–62
Charlson score 0–1 25/127 1 79 70–86
Charlson score 2+ 26/66 3.32 1.78–6.19 0.0002 37 20–54
* Only those without neoadjuvant hormonal treatment.
Table 2.  Results of the competing risk analyses concerning dis-
ease-specific mortality using two-sided stratifications
Category Proportion
of events
10-year 
cumulative 
disease-
specific 
mortality, %
95% CI p
All patients 31/193 18 12–25
Age <70 years 22/155 16 9–23
Age 70+ years 9/38 28 7–50 0.24
Gleason score <8 5/88 5 1–10
Gleason score 8–10 26/105 31 19–42 <0.0001
pT 2 2/44 5 0–15
pT 3–4 29/149 22 14–30 <0.0001
1–2 positive nodes 20/148 15 8–22
>2 positive nodes 11/45 30 13–47 0.08
PSA <10 ng/ml* 9/47 14 6–22
PSA 10+ ng/ml* 13/104 20 5–34 0.11
ASA class 1–2 12/166 19 12–26
ASA class 3 3/27 15 0–34 0.46
NYHA class 0–1 29/187 17 11–24
NYHA class 2+ (9 years) 2/6 37 0–56 0.51
CCS class 0–1 29/184 18 11–25
CCS class 2+ 2/9 22 0–60 0.64
Charlson score 0–1 18/127 14 7–21
Charlson score 2+ 13/66 28 12–43 0.18
* Only those without neoadjuvant hormonal treatment.
Table 3.  Results of the competing risk analyses concerning com-
peting mortality using two-sided stratifications
Category Proportion
of events
10-year
cumulative 
competing
mortality, %
95% CI p
All patients 20/193 15 9–22
Age <70 years 11/155 9 3–15
Age 70+ years 9/38 38 8–69 0.0319
Gleason score <8 7/88 12 3–21
Gleason score 8–10 13/105 19 8–30 0.26
pT 2 3/44 11 0–23
pT 3–4 17/149 17 9–25 0.20
1–2 positive nodes 11/148 12 5–19
>2 positive nodes 9/45 26 8–45 0.16
PSA <10 ng/ml* 2/47 17 0–45
PSA 10+ ng/ml* 12/104 15 6–24 0.30
ASA class 1–2 12/166 10 4–16
ASA class 3 8/27 46 16–77 0.0175
NYHA class 0–1 18/187 14 8–21
NYHA class 2+ (9 years) 2/6 41 0–100 0.34
CCS class 0–1 16/184 13 7–20
CCS class 2+ 4/9 44 3–89 0.09
Charlson score 0–1 7/127 7 1–12
Charlson score 2+ 13/66 35 16–54 0.0078
* Only those without neoadjuvant hormonal treatment.
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corresponding figures were clearly lower (53 and 59%). 
With 60% (disease-specific survival) and 52% (overall 
survival), Schumacher et al.  [10] reported survival rates 
narrowly identical with those in the deferred treatment 
arm in the randomized trial of Messing et al.  [9] . The au-
thors used a comparable deferred hormonal treatment 
regimen but a more extended lymph node dissection with 
an average of 22 removed nodes  [10] . Extended lymph 
node dissection removing about 50% more lymph nodes 
 [10] may be supposed to include more patients with low 
volume lymph node involvement. The impaired survival 
rate in the cited study  [10] compared to the early treat-
ment arm of the trial of Messing et al.  [9] and the current 
study suggests that early (adjuvant) hormonal treatment 
has a greater impact on the outcome of lymph node-pos-
itive disease after radical prostatectomy than the number 
of removed nodes.
 This study confirms the prognostic significance of the 
threshold of 2 involved lymph nodes found by others  [8, 
10] . In agreement with these other studies  [8, 10] , in our 
series, there was no significant difference between pa-
tients with 1 and 2 positive nodes (HR 1.41, 95% CI 0.63–
3.16, p = 0.41 in univariate analysis). The Gleason score 
of the prostatectomy specimen was an independent prog-
nostic factor identified in this ( table 3 ) as well as in sev-
eral other studies  [10–12] , whereas other authors did not 
find independent prognostic significance of the Gleason 
score in node-positive patients  [2, 13] .
0
20
40
60
80
100
0 risk factors
1 risk factor
2–3 risk factors
O
ve
ra
ll 
su
rv
iv
al
 (%
)
Years after radical prostatectomy
0 2 4 6 8 10 12 14 16
0
20
40
60
80
100
0 risk factors
1 risk factor
2–3 risk factors
D
is
ea
se
-s
p
ec
ifi
c 
su
rv
iv
al
 (%
)
Years after radical prostatectomy
0 2 4 6 8 10 12 14 16
 Fig. 1. Kaplan-Meier overall survival 
curves stratified into three different risk 
groups by the risk factors (0 risk factors:
n = 61; 1 risk factor: n = 84; 2–3 risk factors: 
n = 48) identified in the multivariate anal-
ysis (log-rank tests: 0 vs. 1 risk factor: p = 
0.0219; 0 vs. 2–3 risk factors: p  ! 0.0001;
1 vs. 2–3 risk factors: p  ! 0.0001). When 
age was disregarded as a risk factor, the re-
sulting survival curves were somewhat less 
clearly separated (p values ranging be-
tween  ! 0.0001 and 0.06). 
 Fig. 2. Disease-specific survival (100% mi-
nus cumulative disease-specific mortality 
rate; deaths from causes other than pros-
tate cancer were considered competing 
events) stratified into three different risk 
groups by the risk factors identified in the 
multivariate analysis (Pepe-Mori tests:
0 vs. 1 risk factor: p = 0.0098; 0 vs. 2–3 risk 
factors: p = 0.0005; 1 vs. 2–3 risk factors:
p = 0.09). When age was disregarded as a 
risk factor, the resulting survival curves 
were somewhat less clearly separated (p 
values ranging between 0.0002 and 0.39). 
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 The role of age as a prognostic factor in patients with 
positive lymph nodes in this study is difficult to interpret. 
Whereas with a threshold of 70 years, age was a strong 
independent predictor of overall survival, this was no 
longer the case when a threshold of 65 years was chosen 
( table  4 ). An acceptance of higher comorbidity in men 
over 70 years referred for radical treatment with particu-
larly unfavorable tumor-related risk factors could be a 
possible explanation of this phenomenon that vanished 
when the elderly subgroup is diluted by less strictly se-
lected younger patients.
 Whereas, generally, after radical prostatectomy com-
peting mortality clearly outweighs prostate cancer-spe-
cific mortality  [14] , in lymph node-positive patients the 
proportion of disease-specific mortality is higher  [15] . In 
the current study, with 18% disease-specific and 15% 
competing mortality ( tables 1 ,  2 ), this difference was, 
however, moderate. In contrast, in a recently published 
large multicentric study, disease-specific mortality su-
perseded competing mortality at 10 years by 67–540% 
 [15] . With 10-year survival differences between low-risk 
and high-risk groups of 32–47% ( table 1 ), the prognostic 
impact of comorbidity in the univariate analysis in this 
study with lymph node-positive patients was clearly 
higher than seen after radical prostatectomy in general. 
In a radical prostatectomy series from the pre-PSA era, 
there was only a 22% 10-year overall survival difference 
between the Charlson score classes 0 and 2 or higher  [16] . 
In more recent studies, this difference was even lower 
with only 7–12%  [17, 18] . In our series, both comorbidity 
and tumor-related variables seemed to be associated with 
the other endpoint to some extent ( tables 2 ,  3 ). Since none 
Table 4.  Cox proportional hazard models identifying independent predictors of overall survival in patients with 
lymph node-positive prostate cancer
Category Hazard ratio 95% CI p
Model with 70 years as age threshold
Age 70+ years versus younger 2.99 1.65–5.42 0.0003
Gleason score 8–10 versus lower 3.14 1.60–6.16 0.0008
3 or more positive nodes versus 1–2 2.00 1.12–3.56 0.0193
Model with 65 years as age threshold
Gleason score 8–10 versus lower 3.18 1.63–6.22 0.0007
3 or more positive nodes versus 1–2 2.26 1.27–4.03 0.0055
U sing an age threshold of 65 years instead of 70 years eliminated age as an independent predictor of overall 
survival. With 65 years as threshold, already in the univariate analysis there was no detectable association be-
tween age and overall survival (HR 1.49, 95% CI 0.86–2.61, p = 0.16). 
Table 5.  Overall prostate cancer-specific and competing mortality in patients with 0–1 compared with patients 
with 2–3 of risk factors (Gleason score 8–10, >2 positive nodes and age ≥70 years)
C ategory Cumulative mortality rate at 10 years
All causes
%
p* Prostate
cancer, %
p** Competing
causes, %
p**
0–1 risk factor (n = 145) 21 12 9
95% CI 14–31 6–18 3–15
2–3 risk factors (n = 48) 71 <0.0001 37 0.0090 33 0.0210
95% CI 53–86 18–56 14–53
Wh en age was disregarded as a risk factor and patients with 0–1 were compared with those with 2 risk fac-
tors, the survival differences were less clear (overall survival: 88 vs. 52%, p < 0.0001; prostate cancer-specific 
mortality: 15 vs. 36%, p = 0.06; competing mortality: 13 vs. 27%, p = 0.22). * log-rank test, ** Pepe-Mori test.
 Prognosis in Lymph Node-Positive 
Prostate Cancer 
Urol Int 2012;89:148–154 153
of the trends did reach the significance level, these small 
differences could be ignored. It may, however, be conceiv-
able that there was some interaction between adverse tu-
mor-related parameters and serious comorbidity result-
ing in particularly high mortality rates from both causes 
combined. Survival in progressive prostate cancer dis-
ease may well be negatively influenced by serious con-
comitant benign diseases and, conversely, progressive 
prostate cancer might have overproportionally increased 
mortality in patients with serious comorbidity. The find-
ing of increased mortality both from prostate cancer and 
from competing causes in patients with 2–3 risk factors 
( table 5 ) possibly supports this hypothesis. Since almost 
all patients in this sample received hormonal treatment, 
an aggravating effect of hormone ablation on preexisting 
comorbid conditions  [19] may also be taken into consid-
eration.
 Altogether, the outcome of lymph node-positive pa-
tients was more heterogeneous than that of the general 
radical prostatectomy population. In the latter, in one 
large series, the overall survival rates ranged between 
70% (positive nodes, age 70–79 years) and 98% (Gleason 
score 6, age  ! 60 years)  [15] . In contrast, in patients with 
positive lymph nodes in our study, the difference between 
the most (Gleason score  ! 8,  ! 3 positive nodes,  ! 70 years, 
90% 10-year overall survival) and the least favorable 
groups (2–3 of the risk factors Gleason score 8–10, 3 or 
more positive nodes, 70 years or older, 29% 10-year over-
all survival;  fig.  1 ) was clearly higher. The wide prog-
nostic spectrum of lymph node-positive prostate cancer 
should be taken into consideration when different treat-
ment options (for instance radical prostatectomy or adju-
vant radiotherapy) are compared. Even minor differences 
in the selection of good risks into the active treatment 
arms might result in outcome differences. The overall 
survival curve of the least favorable subset of patients in 
this study ( fig.  1 ) was narrowly congruent to that ob-
served in patients in whom radical prostatectomy was 
aborted because of positive lymph nodes  [20] . In contrast, 
the most favorable subset had a higher survival probabil-
ity than lymph node-positive patients receiving adjuvant 
radiotherapy  [21] . Although efforts have been undertak-
en to control for possible selection effects  [20, 21] , uncer-
tainties remain. It seems questionable whether it will pos-
sible to reliably evaluate more aggressive treatment strat-
egies (which are most likely to be offered to patients with 
favorable risk factors) for node-positive disease without 
performing randomized trials. Several clinically mean-
ingful questions deserve further investigation in ran-
domized trials in this patient population, such as timing 
and duration of hormonal therapy, the role of radical 
prostatectomy in men with gross lymph node involve-
ment and that of adjuvant radiotherapy.
 This study has several limitations. The cause of death 
was determined by clinical judgment and not by autopsy. 
Due to the retrospective setting, there was no uniform 
follow-up regimen and it was not possible to reliably de-
termine postoperative treatment details other than the 
timing of commencement of hormonal treatment and 
endpoints other than mortality. 22% of patients had re-
ceived neoadjuvant hormonal treatment which can lead 
to false Gleason score upgrading  [22] . We checked wheth-
er this effect was of relevance in this study and found no 
overall survival differences between patients with a Glea-
son score of 8–10 with and without neoadjuvant hormon-
al therapy (10-year survival 49.1% in patients with vs. 
53.1% in patients without neoadjuvant hormonal therapy, 
HR 1.14, 95% CI 0.55–2.34, p = 0.73). Thus, it is unlikely 
that neoadjuvant hormonal therapy did impair the prog-
nostic validity of the Gleason score in this sample. There-
fore, we decided not to exclude patients with neoadjuvant 
hormonal treatment from analysis.
 Conclusion 
 Some of the excess mortality in patients with poor-risk 
lymph node-positive prostate cancer (those with 2–3 of 
the risk factors age 70 years or older, Gleason score 8 or 
higher or more than 2 involved lymph nodes) may be at-
tributed to increased competing mortality. Interaction 
between comorbid diseases and hormonally treated per-
sistent or progressive prostate cancer may be discussed as 
a possible explanation for this observation.
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